PDE7A and early-onset autosomal dominant Alzheimer disease: Moreover, several preclinical studies have suggested the significance of PDE7 as a novel therapeutic target for neuropsychiatric diseases, including Parkinson’s disease [9], Alzheimer’s disease [10], and addiction [11].